INTERCEPT H3 is the first clinical trial testing a peptide vaccine targeting the H3K27M driver mutation in diffuse midline gliomas, combined with radiation and the immune checkpoint inhibitor atezolizumab.
Nearly 100% of DMGs carry H3K27MThe H3K27M mutation is present as a clonal driver in almost all diffuse midline gliomas, making it an ideal peptide vaccine target because immune escape through mutation loss is unlikely.
What the researchers found
This is a trial protocol paper, not a results paper. The key preclinical finding supporting the trial is that the H3K27M-vac peptide vaccine induced mutation-specific immune responses and suppressed growth of H3K27M-positive tumors in MHC-humanized rodent models.
The trial design calls for 15 adult patients with newly diagnosed H3K27M-mutant diffuse midline gliomas to receive the 27-amino-acid peptide vaccine alongside radiation therapy and the PD-L1-targeting antibody atezolizumab. Vaccines are administered bi-weekly during radiation, then every 6 weeks for a total of 11 doses.
Why it matters
Diffuse midline gliomas are among the most devastating cancers with no effective treatments. The H3K27M mutation is an ideal vaccine target because it is clonal (present in virtually all tumor cells), tumor-specific, and drives the disease. If this peptide vaccine can safely generate immune responses in patients, it could open a new treatment avenue for a cancer that is currently untreatable.
How the study worked
Non-controlled, open-label, single-arm, multicenter Phase I clinical trial across multiple German centers. Fifteen adult patients with newly diagnosed H3K27M-mutant diffuse midline gliomas will be enrolled. The 27mer peptide vaccine H3K27M-vac is administered alongside standard radiotherapy, followed by combination treatment with atezolizumab. A safety lead-in enrolls the first 3 patients sequentially. Primary endpoints are safety, tolerability, and immunogenicity.
What this study cannot tell us
This is a trial protocol, not a results paper — no efficacy or safety data from human patients are available yet. The trial is small (15 patients) and uncontrolled, designed primarily for safety assessment. The patient population is limited to adults, while diffuse midline gliomas also affect children. Success in rodent models does not guarantee clinical efficacy. The open-label, single-arm design does not allow comparison to standard of care.
How to read the evidence
This is a Phase I clinical trial protocol with supporting preclinical data from rodent models. No human clinical results have been reported yet. The evidence supports feasibility but efficacy remains to be demonstrated.
When this study was published
Published in 2023 with trial registration NCT04808245, this trial is part of the current wave of neoantigen-targeting peptide vaccine trials in oncology.
The bigger picture
Peptide vaccines targeting tumor-specific neoantigens represent a growing field in cancer immunotherapy. The H3K27M mutation is particularly attractive because it is both a driver mutation and nearly universally present in diffuse midline gliomas, eliminating concerns about tumor heterogeneity and immune escape. The combination with a checkpoint inhibitor (atezolizumab) reflects the emerging consensus that vaccines may work best when paired with drugs that prevent the tumor from suppressing immune responses.
Questions still open
- Will the peptide vaccine generate strong enough immune responses in immunosuppressed brain tumor patients?
- Can the immune system access H3K27M-presenting cells within the blood-brain barrier?
- If safe and immunogenic, will the approach be extended to pediatric patients with diffuse midline gliomas?
Common questions
What is a diffuse midline glioma and why is it so difficult to treat?
How does this peptide vaccine work against brain tumors?
Read the original research
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Neurological research and practice, 5(1), 55
Citation
Grassl, Niklas; Sahm, Katharina; Süße, Heike; Poschke, Isabel; Bunse, Lukas; Bunse, Theresa; Boschert, Tamara; Mildenberger, Iris; Rupp, Anne-Kathleen; Ewinger, Max Philipp; Lanz, Lisa-Marie; Denk, Monika; Tabatabai, Ghazaleh; Ronellenfitsch, Michael W; Herrlinger, Ulrich; Glas, Martin; Krex, Dietmar; Vajkoczy, Peter; Wick, Antje; Harting, Inga; Sahm, Felix; von Deimling, Andreas; Bendszus, Martin; Wick, Wolfgang; Platten, Michael. (2023). INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.. Neurological research and practice, 5(1), 55. https://doi.org/10.1186/s42466-023-00282-4